This study launched new research by independent research firms to study RB as a checkpoint inhibitor to IL-17, IL-23, IL-6 and other IL..,to which implications can be read below.
what's the deal with all these IL numbers ?
When you say "and other IL . . ." is it possible a longer list of IL numbers (than your numbers mentioned in this post), may become involved with Rose Bengal mechanism of action?
A few hours after learning my 40 yr old nephew, who is having a better quality image at U of MI (MRI - as I type) for possible two bilateral large kidney masses. Help??
He is happily married with 5 kids.
Say it isn't so.
I know cryoablation has been used & approved for kidney cancer in USA. Stats in link below, suggest kidney cryoablation should be done in conjunction with the best possible immunotherapy, if it is a tx option.
I wonder if the necrosis issue may limit injection of kidneys with something like rose bengal? Or if it depend on size?
Kidney toxicity concerns should mean many drugs/immunotherapies would not be ideal for kidneys!
Could there be some hope with low toxic PV-10 / RBD ?
Independent trial IND ??
Right To Try perhaps?
Too many questions.
All possible info is welcomed
2019 SITC Conference -Summary
P505 Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12
Maura Vrabel, Francis Gillam, PhD, Jared Hopkins, Khue Nguyen, PhD, David Zaharoff, PhD
NC State University, Raleigh, NC, United States
Correspondence: David Zaharoff (email@example.com)
Clinically, cryoablation is used to treat various types of cancers including certain prostate, liver and kidney tumors
Cryoablation of a single primary tumor resulted in a tumor-free survival rate of 40%. The addition of R848 or DMXAA did not significantly enhance survival, while adding CS/IL-12 resulted in a 90% survival rate (Figure 1). Cured mice were rechallenged with live MB49 cells and then given no further treatment. As of day 70 post rechallenge, the number of tumor free mice out of total survivors were cryo alone (3/4), cryo + CS/IL-12 (5/7), cryo + R848 (2/5), and cryo + DMXAA (1/4). In the bilateral model, the median survival of the cryo + CS/IL-12 group was significantly longer (p = 0.0016) at 49.5 days compared to 26 days for cryo alone (Figure 2). Furthermore, one mouse treated with cryo + CS/IL-12 experienced a complete response up to 90 days post tumor implantation.
IL-12 formulated with chitosan and delivered after cryoablation is superior in treating not only a primary tumor, but also in inducing an abscopal effect on a distant, untreated tumor. Of note, neither DMXAA nor R848 was formulated in a delivery vehicle, as we have yet to optimize these agonists. This work supports further study of cryoablation and IL-12 for in situ vaccination and cancer immunotherapy.